Verrica Pharmaceuticals (VRCA) News
NASDAQ: VRCAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.74-0.145 (-5.03%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VRCA news summary
We found 3 recent headlines mentioning Verrica Pharmaceuticals (VRCA): 0 in the past week and 2 in the past 30 days, most often from GlobeNewswire, Nasdaq. VRCA is making an outsized move today, down 5.03% at $2.74, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Verrica (VRCA) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Verrica Pharmaceuticals headlines
- Verrica (VRCA) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqVRCA, BIO.B
- Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million –GlobeNewswire
- Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million –GlobeNewswire